TriSalus Life Sciences (TLSI) Cash from Financing Activities (2022 - 2026)
TriSalus Life Sciences (TLSI) posted quarterly Cash from Financing Activities of $42.4 million for Q1 2026, up 337.5% year-over-year from $9.7 million in Q1 2025, and up 15201.44% quarter-over-quarter from $277000.0 in Q4 2025.
TriSalus Life Sciences (TLSI) Cash from Financing Activities (2022 - 2026) Analysis & Trends
TriSalus Life Sciences' Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $42.4 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 337.5% year-over-year to $42.4 million; the TTM figure through Mar 2026 stood at $63.5 million (up 42.62% YoY), while the FY2025 annual figure was $30.8 million, down 18.91% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $42.4 million, up from $277000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $42.4 million in Q1 2026, with the low at $43000.0 in Q4 2023.
- The 5-year median for Cash from Financing Activities is $5.9 million (2022), against an average of $10.5 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities sank 99.27% in 2023, then jumped 6862.79% in 2024.
- TriSalus Life Sciences' Cash from Financing Activities stood at $5.9 million in 2022, then tumbled by 99.27% to $43000.0 in 2023, then surged by 6862.79% to $3.0 million in 2024, then sank by 90.75% to $277000.0 in 2025, then surged by 15201.44% to $42.4 million in 2026.
- Business Quant data shows TLSI's Cash from Financing Activities at $42.4 million in Q1 2026, $277000.0 in Q4 2025, and $82000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | -213.50 Mn |
| 10 | TriSalus Life Sciences | 307.22 Mn | 260.94 Mn | 9.90 Mn | -54,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -54,000.00 |
| Jun 30, 2026 | -54,000.00 |
| Mar 31, 2026 | 42.39 Mn |
| Mar 31, 2026 | 42.39 Mn |
| Dec 31, 2025 | 277,000.00 |
| Dec 31, 2025 | 277,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 20.72 Mn |
| Jun 30, 2025 | 20.72 Mn |
| Mar 31, 2025 | 9.69 Mn |
| Mar 31, 2025 | 9.69 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Sep 30, 2024 | 5.82 Mn |
| Sep 30, 2024 | 5.82 Mn |
| Jun 30, 2024 | 25.99 Mn |
| Jun 30, 2024 | 25.99 Mn |
| Mar 31, 2024 | 3.13 Mn |
| Mar 31, 2024 | 3.13 Mn |